Daiichi Sankyo.

Two traditions. One Vision. Adding to the Balance of Life.

The union of Daiichi and Sankyo brings together two pharmaceutical companies bound by a century of vision and a legacy of firsts.

From the discovery of epinephrine to the development of the statin class of lipid-lowering agents, and the development of the first glitazone, which revolutionized long-term control of type 2 diabetes, the people of Daiichi Sankyo remain committed to a unique ideal Adding to the Balance of Life.

To physicians, this means objective data, the highest ethical standards, and a desire to deliver practical human benefits with each product we develop.

To our partners, we balance the strength and stability of our global presence with the spirit, agility, and quick reaction times of much smaller companies.

To our employees, we offer an operational structure that balances creativity with discipline and individualism with collaboration.

To patients, we are committed to developing medications that put lives into balance and add to the balance of life.

We believe good science walks hand-in-hand with humanity and, as we move forward into our next century, Daiichi Sankyo seeks to build on our history of discovery with the development of new therapies in cardiovascular disease, cancer, metabolic disorders, and infection.